Other Species / Isoforms
  UBE2A (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K66-ac
FTEEYPNkPPTVRFV
0 1
UBE2A (human) FTEEYPNkPPTVRFV K66-ac
UBE2A (mouse) FTEEYPNKPPTVRFV K66
K66-ub
FTEEYPNkPPTVRFV
0 16
UBE2A (human) FTEEYPNkPPTVRFV K66-ub
UBE2A (mouse) FTEEYPNkPPTVRFV K66-ub
K75-ub
PTVRFVSkMFHPNVY
0 2
UBE2A (human) PTVRFVSkMFHPNVY K75-ub
UBE2A (mouse) PTVRFVSKMFHPNVY K75
S120-p
LDEPNPNsPANSQAA
Upstream
1 2
Kinase, in vitro:
  • CDK1 (human)
  • CDK2 (human)
Putative in vivo kinases:
  • CDK1 (human)
  • CDK2 (human)
Treatment
  • nocodazole
  • seliciclib
UBE2A (human) LDEPNPNsPANSQAA S120-p
UBE2A (mouse) LDEPNPNSPANSQAA S120
S142-p
REYEKRVsAIVEQsW
0 3
UBE2A (human) REYEKRVsAIVEQsW S142-p
UBE2A (mouse) REYEKRVSAIVEQSW S142
S148-p
VsAIVEQsWRDC___
0 1
UBE2A (human) VsAIVEQsWRDC___ S148-p
UBE2A (mouse) VSAIVEQSWRDC___ S148